A common phosphotyrosine signature for the Bcr-Abl kinase

The Bcr-Abl fusion kinase drives oncogenesis in chronic myeloid leukemia (CML). CML patients are currently treated with the Abl tyrosine kinase inhibitor imatinib, which is effective in early stages of the disease. However, resistance to imatinib arises in later disease stages primarily because of a...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Goss, Valerie L., Lee, Kimberly A., Moritz, Albrecht, Nardone, Julie, Spek, Erik J., MacNeill, Joan, Rush, John, Comb, Michael J., Polakiewicz, Roberto D.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: The American Society of Hematology 2006
Konular:
Neoplasia
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC1895816/
https://ncbi.nlm.nih.gov/pubmed/16497976
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2005-08-3399
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller